United States v. Anthony Smith

CourtCourt of Appeals for the Third Circuit
DecidedApril 22, 2024
Docket22-2799
StatusUnpublished

This text of United States v. Anthony Smith (United States v. Anthony Smith) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Anthony Smith, (3d Cir. 2024).

Opinion

NOT PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT ____________

No. 22-2799 ___________

UNITED STATES OF AMERICA

v.

ANTHONY SMITH, Appellant ____________

On Appeal from the United States District Court for the Western District of Pennsylvania (D.C. No. 2-19-cr-00008-044) District Judge: Honorable J. Nicholas Ranjan ____________

No. 22-2844 ___________

ANTHONY SMITH, a/k/a ANT, a/k/a LIL PO, Appellant ____________

On Appeal from the United States District Court for the Western District of Pennsylvania (D.C. No. 2-13-cr-00057-003) District Judge: Honorable J. Nicholas Ranjan ____________

Submitted Under Third Circuit L.A.R. 34.1(a) April 18, 2024 Before: HARDIMAN, SMITH, and FISHER, Circuit Judges.

(Filed: April 22, 2024)

____________

OPINION * ____________

HARDIMAN, Circuit Judge.

Anthony Smith appeals his judgment of conviction and sentence based on his role

in a drug-trafficking conspiracy. 1 He primarily challenges the sufficiency of the evidence

at trial. He also alleges procedural errors and prosecutorial misconduct. We will affirm.

I

Shortly after being released from prison to a Pittsburgh halfway house in May

2017, Smith met Noah Landfried, the kingpin of an extensive drug-trafficking

organization in western Pennsylvania. Toward the end of the year, Landfried began

selling Smith greeting cards saturated in K2, a synthetic drug designed to mimic

marijuana. Smith resold these K2-laced cards for hundreds of dollars each to prisoners he

knew, as well as to some of his childhood friends. After a federal investigation uncovered

evidence of Smith’s role in selling K2, he was indicted for conspiracy to distribute and

possess with intent to distribute Schedule I, II, and III controlled substances between

* This disposition is not an opinion of the full Court and pursuant to I.O.P. 5.7 does not constitute binding precedent. 1 This conviction is docketed at Case No. 22-2799. Smith also appealed the revocation of his supervised release, which is docketed at Case No. 22-2844. Smith did not raise any argument pertinent to the supervised release appeal. 2 January 2017 and January 2019, in violation of 21 U.S.C. § 846. After ignoring text

messages from his probation officer ordering him to turn himself in, Smith was arrested

in October 2019.

In December 2021, Smith was tried before a jury along with Landfried and Michel

Cercone, another co-conspirator. While testifying at trial, multiple co-conspirators

discussed Smith’s involvement in the distribution of K2. In addition to checks that

prisoners had mailed to Smith, the Government presented test results confirming the K2

associated with Landfried contained 5F-MDMB-PINACA, a Schedule I controlled

substance since April 10, 2017. Smith testified that he bought “a few” K2-laced greeting

cards from Landfried about 10 different times. App. 1167. He even admitted that he knew

it was “a crime,” but that he wanted “to make a few extra bucks.” App. 1160–61.

The jury convicted Smith. At sentencing, the District Court overruled Smith’s

objection to the drug-quantity calculation in the Presentence Investigation Report (60 to

80 kilograms of converted drug weight). The District Court then sentenced Smith to 51

months’ imprisonment followed by 6 years’ supervised release. Smith timely appealed

his conviction and sentence for the drug-trafficking crime. 2

II

Smith argues that the jury’s verdict should be overturned “[b]ecause no evidence

was established at trial to show that . . . Smith knew that what he possessed was a

substance listed on the schedules, or the identity of the substance he possessed.” Smith

2 The District Court had jurisdiction under 18 U.S.C. § 3231. We have jurisdiction under 28 U.S.C. § 1291 and 18 U.S.C. § 3742. 3 Br. 35. We review this argument for plain error because Smith did not preserve it in the

District Court. United States v. Johnson, 19 F.4th 248, 255 (3d Cir. 2021).

Smith contends that the conspiracy’s underlying offense, 21 U.S.C. § 841(a)(1),

requires the Government to show he was either “aware that what he purchased contained

the specific substances listed” in the indictment or “knew what he possessed as K2 was a

controlled substance . . . at the time that he possessed it.” Smith Br. 28. He is incorrect.

The Government had to prove only that Smith knew K2 was “some unspecified substance

listed on the federal drug schedules.” McFadden v. United States, 576 U.S. 186, 192

(2015). Smith’s admissions at trial demonstrate that he realized as much. Smith not only

knew that selling K2 was a crime, but he understood that K2 produced a “high” similar to

marijuana. App. 1157. Smith also repeatedly attempted to conceal his activities from

prison officials—for instance, by disguising his K2-laced greeting cards as ordinary

cards. And he tried to avoid law enforcement by absconding after he was indicted. All of

this provided strong evidence that Smith possessed the requisite mental state under 21

U.S.C. § 841(a)(1). See McFadden, 576 U.S. at 192 n.1.

Because a rational juror could conclude that Smith conspired to distribute a

Schedule I controlled substance, namely 5F-MDMB-PINACA, Smith cannot show, as is

required under plain-error review, that the jury’s verdict was “devoid of evidence” or

supported by evidence “so tenuous” that his conviction was “shocking.” United States v.

Jabateh, 974 F.3d 281, 300 (3d Cir. 2020).

III

Smith next argues that he was unlawfully subjected to a variance or constructive

4 amendment 3 because: (1) the Government “was permitted to refer to multiple synthetic

cannabinoids listed” in the indictment by a single name (K2) throughout trial, even

though they were scheduled at different times under the Controlled Substances Act,

Smith Br. 35; and (2) the District Court’s jury instructions “implicated all federal drug

abuse laws, including the Analogue Act,” which was not charged in the indictment, Smith

Br. 37. We review these arguments for plain error because Smith raises them for the first

time on appeal. United States v. Vosburgh, 602 F.3d 512, 531 (3d Cir. 2010).

While counsel for the Government—and Smith—did refer broadly to specific

synthetic cannabinoids as K2 throughout the trial, Smith’s suggestion that the jury might

have convicted him based on a controlled substance not listed in the indictment is

speculative. “[W]e presume that the jury followed the District Court’s instructions,”

United States v. Fallon, 61 F.4th 95, 113 (3d Cir. 2023), and the District Court carefully

instructed the jury that: (1) the charges against Smith were “contained in the indictment,”

App.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Vosburgh
602 F.3d 512 (Third Circuit, 2010)
United States v. Olano
507 U.S. 725 (Supreme Court, 1993)
United States v. Russell A. Werme
939 F.2d 108 (Third Circuit, 1991)
United States v. Robert E. Brennan
326 F.3d 176 (Third Circuit, 2003)
United States v. Dorothea Daraio
445 F.3d 253 (Third Circuit, 2006)
McFadden v. United States
576 U.S. 186 (Supreme Court, 2015)
United States v. Mohammed Jabateh
974 F.3d 281 (Third Circuit, 2020)
United States v. Joseph Johnson, Jr.
19 F.4th 248 (Third Circuit, 2021)
United States v. Gimy Rodriguez
40 F.4th 117 (Third Circuit, 2022)
United States v. Gibbs
190 F.3d 188 (Third Circuit, 1999)
United States v. Castro
776 F.2d 1118 (Third Circuit, 1985)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Anthony Smith, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-anthony-smith-ca3-2024.